Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $95.21 ($717K) on 2026-08-03, disclosed to the SEC on 2026-08-05.
Scheduled sale ($717k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $95.21 | 5,100 | $486K | 67.7% |
| 2 | $96.30 | 2,300 | $221K | 30.9% |
| 3 | $97.10 | 100 | $10K | 1.4% |
| Total | $95.57 avg | 7,500 | $717K | 100% |
| Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $533K | — | Filing → |